Release Date: July 30, 2018
Expiration Date: July 30, 2019
Media: Internet - based
Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology Strategies
is an online activity based on the live symposium held adjunct to the annual urology meeting in San Francisco. Clinical decision making in the setting of bladder cancer has dramatically changed over recent years with the approvals of several immuno-oncology agents that have improved patient outcomes. Their introduction has raised some clinical questions and challenges regarding optimal treatment selection, duration of treatment, sequencing, as well as identification and management of pseudoprogression and unique toxicities. Use of these agents across multiple lines of therapy for advanced bladder cancer and the potential expansion of their use to early-stage disease makes it imperative that urologists, as members of the multidisciplinary care team, understand both new data and best practices related to the use of immuno-oncology strategies, including proactively monitoring, mitigating, and managing immune-related adverse events. This interactive symposium will bring together a multidisciplinary faculty of renowned experts in urology, medical oncology, and immune-oncology to review practice-changing data and discuss their impact on patient care. Brief didactic presentations will be followed by “real-world” clinical case presentations and discussions that facilitate interpretation and application of the evidence. The faculty will also share their forward-looking perspectives on the bladder cancer treatment horizon based on recently reported and anticipated clinical trial data.
CME Activity Table of Contents
Module 1: A Primer for Urologists on Immuno-Oncology: Mechanisms and Rationale to Apply These Strategies to Bladder Cancers
Module 2: Assessment of Evolving Strategies for Bladder Cancer in Multiple Lines of Therapy
Module 3: The Present Role and Future Directions of Immuno-Oncology for Nonmuscle Invasive Bladder Cancer
Acknowledgment of Commercial Support
This activity is supported by educational grants from AstraZeneca, Incyte, and Merck Sharp & Dohme Corp.
Instructions for This Activity and Receiving Credit
You will need to login to participate in the activity.
Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
At the end of the activity, “educational content/video files” will be available for your reference.
In order to receive a CME/CE certificate, participants must complete the activity.
Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.
This educational program is directed toward urologists, oncologists, and researchers interested in the treatment of bladder cancers. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with bladder cancers are invited to participate.
At the conclusion of this activity, participants should be better prepared to:
Explain the mechanistic rationale that underlies the investigation and clinical development of immunotherapeutic approaches to manage bladder cancer
Evaluate pivotal trial findings from studies that have evaluated immunotherapies for the management of patients with bladder cancer and emerging information concerning the role of biomarkers, combination strategies, and adjuvant approaches in this regard
Place practice-changing evidence concerning the management of bladder cancer in the context of managing these patients in contemporary urological cancer care settings
Identify and proactively mitigate the impact of treatment-related toxicities among patients with bladder cancer
Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, CT
Disclosure: Grant/Research Support: Agensys, AstraZeneca, Bayer, Clovis, Dendreon, Eli Lilly, Endocyte, Genentech, Innocrin, Johnson and Johnson, Lilly, MedImmune, Medivation, Merck, Millineum, Novartis, Pfizer, Progenics, Roche Laboratories, Sanofi Aventis, Sotio; Consultant: Astellas, AstraZeneca, Bayer, Bellicum, Dendreon, Exelixis, Ferring, Johnson and Johnson, Lilly, Medivation, Millineum, Pfizer, Roche Laboratories, Sanofi Aventis; Stock/Shareholder: Bellicum, Tyme
Charles Drake, MD, PhD
Professor of Oncology and Immunology
Director, Genitourinary Cancer Program
Co-director of the Immunotherapy Program
Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center
New York, NY
Disclosure: Grant/Research Support: Aduro Biotech, Bristol Myers Squibb, Janssen; Consultant: Agenus, Dendreon, NexImmune, ImmunExcite, Janssen, Lilly, Merck, Pierre Fabre, Roche/Genentech; Other: Patents: Az Medimmune, BMS, Janssen Ownership Interests: Compugen, Harpoon, Kleo, Potenza, Tizona
Leonard G. Gomella, MD, FACS
The Bernard W. Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Associate Director, Jefferson Kimmel Cancer Center
Clinical Director Jefferson Kimmel Cancer Center Network
Thomas Jefferson University
Disclosure: Consultant: Astellas, MDXHealth, Janssen, Merck, Pfizer
Guru P. Sonpavde, MD
Bladder Cancer Director
Dana-Farber Cancer Institute
Disclosure: Grant/Research Support: Boehringer-Ingelheim, Bayer, Onyx-Amgen, Pfizer, Merck, Celgene; Consultant: Pfizer, Genentech, Novartis, Argos, Merck, Sanofi, Agensys/Astellas, Clinical Care Options, AstraZeneca, Biotheranostics, Exelixis, BMS, Janssen, Amgen, Eisai, NCCN, EMD Serono; Other: Author of educational chapter: Uptodate;
The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.
Disclosure Policy and Resolution of Conflicts of Interest
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
PER Pulse Recap™
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology Strategies
is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in May 2018 in San Francisco, California. In this online activity, program chair, Daniel Petrylak, MD, and expert faculty discuss the evolving role of immunotherapy in the treatment of bladder cancers. It features commentary on:
PER Pulse Recap (1 of 3)
A Primer for Urologists on Immuno-oncology: Mechanisms and Rationale to Apply These Strategies to Bladder Cancers by Charles Drake, MD, PhD
Assessment of Evolving Strategies for Bladder Cancer in Multiple Lines of Therapy by Daniel Petrylak, MD, and Guru P. Sonpavde, MD
The Present Role and Future Directions of Immuno-oncology for Nonmuscle- Invasive Bladder Cancer by Leonard G. Gomella, MD, FACS, and Daniel Petrylak, MD
This first of 3 PER Pulse™ Recaps summarizing the online program focuses on Dr Drake’s answers to questions about the current state and future outlook of immunotherapy in bladder cancer, during which he discussed:
The rationale for using modern immunotherapeutics in the treatment of bladder cancer and how they differ from conventional immune therapies that have been used for the past few decades to treat bladder cancer
Immunotherapy for early-stage versus advanced bladder cancer and how the treatment landscape may change over the next 10 years
Study data showing the difference in outcomes and the characteristics of disease response between immunotherapy and systemic therapy in bladder cancer
Future strategies for selecting patients with bladder cancer for immunotherapy and prognosticating risk
PER Pulse Recap (2 of 3)
This second of 3 PER Pulse™ Recaps summarizing the online program focuses on Drs Petrylak’s and Sonpavde’s answers to questions about recent FDA approvals and ongoing clinical trials in the treatment of bladder cancer involving multiple lines of therapy, during which they discussed:
How recent advances in immunotherapy has affected their own practices and the lives of their patients
Recent FDA approvals for checkpoint inhibitors in the treatment of bladder cancer, including in the platinum refractory setting
Potential immune-related adverse events and clinical practice guidelines for managing them
The potential clinical impact of important, ongoing studies of immunotherapy for bladder cancer, including immuno-oncology-combination strategies
Approaches for improving the multidisciplinary continuum of care for patients with early-stage bladder cancer, including muscle-invasive and nonmuscle-invasive bladder cancer
PER Pulse Recap (3 of 3)
This third of 3 PER Pulse™ Recaps summarizing the online program focuses on Dr Gomella’s answers to questions about immunotherapy for the treatment of nonmuscle-invasive bladder cancer, during which he discussed:
His evolving approach toward use of BCG and interferon in the treatment of nonmuscle invasive bladder cancer
What the future may hold for immunotherapy in nonmuscle-invasive bladder cancer and what urologists need to know about it right now
Ongoing studies that could affect the treatment options for nonmuscle-invasive bladder cancer
Approaches for improving the multidisciplinary continuum of care for patients with nonmuscle-invasive bladder cancer